Obesity in patients with COVID-19: a systematic review and meta-analysis

Abstract

Background: Obesity is common in patients with coronavirus disease 2019 (COVID-19). The effects of obesity on clinical outcomes of COVID-19 warrant systematical investigation. Objective: This study explores the effects of obesity with the risk of severe disease among patients with COVID-19. Methods: Body mass index (BMI) and degree of visceral adipose tissue (VAT) accumulation were used as indicators for obesity status. Publication databases including preprints were searched up to August 10, 2020. Clinical outcomes of severe COVID-19 included hospitalization, a requirement for treatment in an intensive care unit (ICU), invasive mechanical ventilation (IMV), and mortality. Risks for severe COVID-19 outcomes are presented as odds ratios (OR) and 95% confidence interval (95%CI) for cohort studies with BMI-defined obesity, and standardized mean difference (SMD) and 95%CI for controlled studies with VAT-defined excessive adiposity. Results: A total of 45, 650 participants from 30 studies with BMI-defined obesity and 3 controlled studies with VAT-defined adiposity were included for assessing the risk of severe COVID-19. Univariate analyses showed significantly higher ORs of severe COVID

Visceral Adiposity Elevates the Risk of Critical Condition in COVID‐19: A Systematic Review and Meta‐Analysis

“…A recent meta-analysis by Huang et al has come to the same conclusion (20); they have found higher VAT values in patients with critical condition, as well. However, their search interval was shorter, and we included two additional studies in the meta-analyses (9,11).…”

Susceptibility of the patients infected with Sars-Cov2 to oxidative stress and possible interplay with severity of the disease

“…Comorbidities are highly prevalent in patients who require intensive care. Several conditions have been demonstrated to be related to disease severity and poor outcomes, such as diabetes, cardiovascular diseases, and obesity [ [30] , [31] , [32] ]. Additionally, severity is also related to a high comorbidity index [ 33 ].…”

A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India

“…Previous reviews published in this journal and elsewhere have highlighted the following issues relevant to COVID-19: a) relationship between COVID-19 and diabetes/other comorbidities [ [11] , [12] , [13] , [14] ], b) appropriate diagnosis and management of diabetes and other endocrine disorders during the pandemic [ [15] , [16] , [17] , [18] , [19] , [20] , [21] ], and c) the evolving role of telemedicine consultations in the era of COVID-19 and its pitfalls [ 22 , 23 ]. Given the huge burden of COVID-19 in our country, expertise for close supervision of diabetes management may not always be available and treatment decisions may need to be taken by non-experts or healthcare personnel from a non-clinical specialty deployed in COVID facilities.…”